Organon & Co. Reports Board Changes and Officer Compensation Updates

Ticker: OGN · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1821825

Organon & CO. 8-K Filing Summary
FieldDetail
CompanyOrganon & CO. (OGN)
Form Type8-K
Filed DateJan 21, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

Related Tickers: OGN

TL;DR

Organon's board is changing, and exec pay is getting updated.

AI Summary

Organon & Co. announced on January 15, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of a director and the election of a new director, along with updates to the compensatory arrangements for certain officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing reports routine corporate governance changes and compensation adjustments, which typically carry low inherent risk.

Key Players & Entities

FAQ

What specific changes were made to the board of directors?

The filing indicates the departure of a director and the election of a new director, though their names are not specified in this excerpt.

When did the reported events occur?

The earliest event reported occurred on January 15, 2025.

What is Organon & Co.'s Commission File Number?

Organon & Co.'s Commission File Number is 001-40235.

Where are Organon & Co.'s principal executive offices located?

Organon & Co.'s principal executive offices are located at 30 Hudson Street, Floor 33, Jersey City, NJ 07302.

What type of information is being reported in this 8-K filing?

This 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-01-21 07:01:34

Key Financial Figures

Filing Documents

02 Departure of Directors or Certain Officers; Election of Directors;

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 15, 2025, Organon & Co. (the " Company ") announced that effective January 15, 2025, Susanne Fiedler ceased performing her functions as Chief Commercial Officer. Ms. Fiedler will serve as a senior advisor to the Company until her departure, which is currently expected to be on or about April 30, 2025. Exhibit No. Description 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Organon & Co. By: /s/ Kirke Weaver Name: Kirke Weaver Title: General Counsel & Corporate Secretary Dated: January 21, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing